Abstract：In the previous study, we prepared a divalent combination DNA vaccine pOPRL+pOPRF, which could induce good immune response and protective efficacy. To explore the optimal immunization dose of this divalent combination DNA vaccine, in this study, mice were vaccinated with 25 μg, 50 μg, 100 μg and 200 μg of this DNA vaccine with empty vector pcDNA 3.1(+) and PBS as negative control. Then the levels of serum antibody, interferon-γ (IFN-γ) and interleukin-2 (IL-2) concentrations were determined and lymphocyte proliferation assays were performed. After challenging with virulent P. aeruginosa, protective efficacy was evaluated. Following vaccination, the serum antibodies, stimulation index (SI) values and the concentrations of the two cytokines in mice vaccinated with 100 μg and 200 μg of divalent combination DNA vaccine were significantly higher than in those mice vaccinated with 25 μg and 50 μg DNA vaccine (P<0.05). Additionally, the concentrations of IFN-γ and IL-2 in mice immunized with 100 μg divalent combination DNA vaccine were higher than those mice immunized with 200 μg DNA vaccine after the third vaccination. The protective rates of 25 μg, 50 μg, 100 μg and 200 μg of the pOPRL+pOPRF DNA vaccine were 35%, 45%, 85% and 70%, respectively. The results indicated that the immune efficacy of the pOPRL+pOPRF DNA vaccine enhanced with the increase of immunization dose to some degree, but not the higher the better. The optimal immunization dose of pOPRL+pOPRF DNA vaccine in mice is 100 μg.
宫强, 阮梦蝶, 郭洁真, 杜珍奇. 铜绿假单胞菌二价组合DNA疫苗pOPRL+pOPRF最佳免疫剂量研究[J]. 中国人兽共患病学报, 2020, 36(7): 539-543.
GONG Qiang, RUAN Meng-die, GUO Jie-zhen, DU Zhen-qi. Study on the optimal immunization dose of divalent combination DNA vaccine pOPRL+pOPRF DNA vaccine of Pseudomonas aeruginosa. Chinese Journal of Zoonoses, 2020, 36(7): 539-543.
[1] Talwalkar JS, Murray TS.The Approach to Pseudomonas aeruginosa in Cystic Fibrosis[J]. Clinics Chest Med, 2016, 37: 69-81. DOI: 10.1016/j.ccm.2015.10.004 [2] Chen J, Chen Y, Hua P, et al.Risk assessment of infected children with Pseudomonas aeruginosa pneumonia by combining host and pathogen predictors[J]. Infect Genet Evol, 2018, 57(1): 82-87. DOI: 10.1016/j.meegid.2017.11.015 [3] Gu J, Li X Yang M, et al. Therapeutic effect of Pseudomonas aeruginosa phage YH30 on mink hemorrhagic pneumonia[J]. Vet Microbiol, 2016, 190(7): 5-11. DOI: 10.1016/j.vetmic.2016.03.016 [4] Pang Z, Raudonis R, Glick BR, et al.Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies[J]. Biotechnol Adv, 2019, 37(1): 177-192. DOI: 10.1016/j.biotechadv.2018.11.013 [5] Lister PD, Wolter DJ, Hanson ND.Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms[J]. Clin Microbiol Rev, 2009, 22(4): 582-610. DOI: 10.1128/CMR.00040-09 [6] Trinh TD, Zasowski EJ, Claeys KC, et al.Multidrug-resistant Pseudomonas aeruginosa lower respiratory tract infections in the intensive care unit: Prevalence and risk factors[J]. Diagn Microbiol Infect Dis, 2017, 89(1): 61-66. DOI: 10.1016/j.diagmicrobio.2017.06.009 [7] Shariati A, Azimi T, Ardebili A, et al.Insertional inactivation of oprD in carbapenem-resistant Pseudomonas aeruginosa strains isolated from burn patients in Tehran, Iran[J]. New Microbes New Infect, 2018, 21(1): 75-80. DOI: 10.1016/j.nmni.2017.10.013 [8] Rashid MR, Naz A, Ali A, et al. Prediction of vaccine candidates against Pseudomonas aeruginosa: An integrated genomics and proteomics approach[J]. Genomics, 2017 (3/4), 109: 274-283. DOI: 10.1016/j.ygeno.2017.05.001 [9] Gong Q, Ruan MD, Niu MF, et al.Immune efficacy of DNA vaccines based on oprL and oprF genes of Pseudomonas aeruginosa in chickens[J]. Poultry Science, 2018, 97(12): 4219-4227. [10] 宫强, 阮梦蝶, 彭永刚, 等. 铜绿假单胞菌外膜蛋白L和F基因单价、融合和联合DNA疫苗的免疫效果[J]. 中华微生物学和免疫学杂志, 2019, 39(2): 125. DOI: 10.3760/cma.j.issn.0254-5101.2019.02.008 [11] Gong Q, Qu N, Niu MF, et al.Immune responses and protective ef cacy of a novel DNA vaccine encoding outer membrane protein of avian Pasteurella multocida[J]. Vet Immunol Immunop, 2013, 15(3/4): 317-324. DOI: 10.1016/j.vetimm.2013.01.001 [12] Price BM, Legutki JB, Galloway DR, et al.Enhancement of the protective efficacy of an oprF DNA vaccine against Pseudomonas aeruginosa[J]. FEMS Immunol Med Microb, 2002, 33(2): 89-99. DOI: 10.1016/S0928-8244(02)00279-1 [13] Staczek J, Gilleland LB, van der Heyde HC, et al. DNA vaccines against chronic lung infections by Pseudomonas aeruginosa[J]. FEMS Immunol Med Mic, 2003, 37(2-3): 147-153. DOI: 10.1016/S0928-8244(03)00075-0 [14] Zuercher AW, Horn MP, Wu H, et al.Intranasal immunisation with conjugate vaccine protects mice from systemic and respiratory tract infection with Pseudomonas aeruginosa[J]. Vaccine, 2006, 24(20): 4333-4342. DOI: 10.1016/j.vaccine.2006.03.007 [15] D ring G, Pier GB. Vaccines and immunotherapy against Pseudomonas aeruginosa[J]. Vaccine, 2008, 26(8): 1011-1024. DOI: 10.1016/j.vaccine.2007.12.007 [16] Mousavi M, Behrouz B, Irajian G, et al.Passive immunization against Pseudomonas aeruginosa recombinant PilA in a murine burn wound model[J]. Microb Pathog, 2016, 101(12): 83-88. DOI: 1016/j.micpath.2016.10.027 [17] Wang F, Li Z, Li L, et al.GP73 was upregulated in PBMC stimulated with ConA but failed to promote lymphocyte proliferation[J]. Cell Biol Int, 2015, 39(3): 334-340. DOI: 10.1002/cbin.10377
2020, Vol. 36 
